TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05717738

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure of TACE is standardized.

Intervention type: DRUG
Intervention: Lenvatinib
Description: 8mg; p.o.; q.d.

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).

Intervention type: DRUG
Intervention: Anti-PD-1 monoclonal antibody
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).

Intervention type: DRUG
Intervention: Bevacizumab Biosimilar IBI305 plus sintilimab
Description: Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Study: NCT04941729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OR3O™ - Dual Mobility System
Description: OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith \& Nephew Oxinium (Ox) femoral head.
Study: NCT05897944

Intervention type: OTHER
Intervention: COPD
Description: A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
Study: NCT05894148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab injection
Description: Group 1: 120mg Q4W，group 2: 200mg Q4W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
Study: NCT05458687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance
Description: * Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome.
Study: NCT06382896

Intervention type: OTHER
Intervention: No intervention
Description: This was an observational study
Study: NCT04672603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Preservation of Denonvilliers' Fascia
Description: Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
Study: NCT06425757

Intervention type: DRUG
Group type: OTHER
Intervention: ciprofol
Description: Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured

Intervention type: DRUG
Group type: OTHER
Intervention: ciprofol
Description: Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
Study: NCT06263738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Hyperthermia
Description: Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Hyperthermia
Description: Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Water Plunge
Description: Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 55 degree (Fahrenheit) water, lasting up to 10 minutes.
Study: NCT05685628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamon dressing
Description: Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal dressing
Description: Use of ACTISORB® as a non-occlusive secondary dressing~CE marked medical device class IIb, without adhesive, consisting of a non-woven nylon envelope containing a layer of activated carbon. ACTISORB® can be applied as a primary or secondary dressing.
Study: NCT06260748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid
Description: 250mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chenodeoxycholic acid
Description: 250mg capsules
Study: NCT06425757

Intervention type: DRUG
Group type: OTHER
Intervention: ciprofol
Description: Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
Study: NCT06260748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chenodeoxycholic acid
Description: 250mg capsules
Study: NCT05717738

Intervention type: DRUG
Intervention: Bevacizumab plus Atezolizumab
Description: Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)

Intervention type: DRUG
Intervention: apatinib plus camrelizumab
Description: Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)

Intervention type: DRUG
Intervention: Sorafenib
Description: 400mg; p.o. bid

Intervention type: DRUG
Intervention: Donafenib
Description: 200mg; p.o. bid
Study: NCT06260748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid Placebo
Description: Placebo to match
Study: NCT01614288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: knee Arthroscopy
Description: Patient undergoes a knee arthroscopy and HTO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No arthroscopy
Description: Patient undergoes an HTO without knee arthroscopy
Study: NCT04987645

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Water-only infusion technique
Description: During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Water infusion and air insufflation
Description: During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
Study: NCT05717738

Intervention type: DRUG
Intervention: Regorafenib
Description: 160 mg; p.o.; q.d.
Study: NCT04579380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
Study: NCT05912530

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention will done

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention will done
Study: NCT05498766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur, Gimeracil and Oteracil Potassium
Description: Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
Study: NCT06475196

Intervention type: DRUG
Intervention: Sintilimab (PD-1 inhibitor)
Description: to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.

Intervention type: DRUG
Intervention: Sintilimab (PD-1 inhibitor)
Description: to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.

Intervention type: DRUG
Intervention: Sintilimab (PD-1 inhibitor)
Description: to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
Study: NCT04632290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STIMO-BSI system implantation
Description: Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
Study: NCT05674084

Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary refill time
Description: CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and \> 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
Study: NCT05475769

Intervention type: DRUG
Intervention: Clinical evaluation
Description: Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
Study: NCT05898646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT06530901

Intervention type: DIAGNOSTIC_TEST
Intervention: Multidimensional ultrasound of the inferior vena cava
Description: Cross-sectional parameters of the inferior vena cava include two-dimensional longitudinal diameter, cross-sectional length and short diameter, circumference, and cross-sectional area, as well as cross-sectional length and short diameter, circumference, and cross-sectional area in three-dimensional imaging
Study: NCT06611631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid pulpotomy
Description: 1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mineral trioxide aggregate pulpotomy
Description: 1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown.
Study: NCT06666855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117B Eye Drops
Description: Investigational Product: 0.002% DE-117B Eye Drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Active Control: 0.005% Latanoprost Eye Drops
Study: NCT06667466

Intervention type: DEVICE
Intervention: Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention
Description: The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.

Intervention type: DEVICE
Intervention: Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention
Description: The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
Study: NCT06672679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Juntos
Description: 6 week family-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource guide
Description: Active control arm will receive a resource guide
Study: NCT06672185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC101
Description: ARC101 will be administered according to an assigned dose schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC101
Description: ARC101 will be administered according to an assigned dose schedule.
Study: NCT06671028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Lidocaine
Description: Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,5%
Description: Popliteal sciatic block using ropivacaine 0.5% 20 mL
Study: NCT06672094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NeuroQ
Description: Two (2) capsules of NeuroQ taken once a day for 60 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two (2) capsules of placebo taken once a day for 60 days.
Study: NCT06671080

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: All of these tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
Study: NCT06671535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate membrane
Description: A polymethylmethacrylate hollow fiber membrane (PMMA membrane) has unique properties including the uniform structure and the adsorption property.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polysulfone membranes
Description: Dialyzers containing polysulfone membranes are widely used for modern dialysis therapies as they allow efficient removal of a broad spectrum of uremic toxins.
Study: NCT06671639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Xi Robotic Surgery System
Description: The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Xi Robotic Surgery System
Description: The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system.
Study: NCT06672224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid Therapy
Description: Given IV
Study: NCT05898646

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Given SC
Study: NCT06046222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-229
Description: Experimental

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06115278

Intervention type: OTHER
Intervention: survey
Description: survey

Intervention type: OTHER
Intervention: survey
Description: survey
Study: NCT06580587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Oral administration
Study: NCT05931705

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire
Study: NCT06023199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Voxelotor is administered orally at a dose of 1500mg daily.
Study: NCT06672224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research or Clinical Assessment Tool
Description: Undergo lymphedema assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPY Elite Fluorescence Imaging
Description: Undergo SPY imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06672796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted Toe Spread Out Exercise
Description: new resistance exercise phase in addition to the standard protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toe Spread Out Exercise
Description: Standart protocol of toe spread out exercise
Study: NCT05819060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib Combination with Bevacizumab
Description: For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.